China NMPA Drug Inspection - Harbin Pharmaceutical Group General Pharmaceutical Factory - Norfloxacin capsules
China NMPA drug inspection for Harbin Pharmaceutical Group General Pharmaceutical Factory published May 11, 2018. Drug: Norfloxacin capsules. The Chongqing Municipal Food and Drug Administration released its second Drug Quality Announcement for 2018 on May 11, 2
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Harbin Pharmaceutical Group General Pharmaceutical Factory published May 11, 2018. Drug: Norfloxacin capsules. The Chongqing Municipal Food and Drug Administration released its second Drug Quality Announcement for 2018 on May 11, 2
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox